StemCell Therapy

NEW YORK, Jan. 23, 2012 /PRNewswire/ -- NeoStem,
Inc.^[1] (NYSE Amex:
NBS) ("NeoStem" or the "Company"), an international
biopharmaceutical company with a focus on cell-based
therapeutic development, today announced that its Chief Medical
Officer, the lead investigator for its PreSERVE Phase
2 clinical trial^[2] for AMR-001
for preservation of heart function in post acute myocardial
infarction patients, and the President of its subsidiary,
Progenitor Cell
Therapy, LLC^[3], have been
invited to present at the Seventh International Conference on
Cell Therapy for Cardiovascular Disease held from January
25-27, 2012 in New York City. The event is being organized by
the Cardiovascular Research Foundation and will be held at the
Myrna L. Daniels Auditorium in the Vivien and Seymour Milstein
Family Heart Center at NYPH/Columbia University Medical Center.

According to the conference, the program will be dedicated to
the evolving field of cell-based therapies being developed for
the repair and regeneration of cardiac and vascular disease, as
well as related diseases such as diabetes and stroke. This
year's conference will focus on preclinical and clinical
studies on the path to commercialization, highlighting the
status of molecular, cell, and tissue products in addition to
delivery systems. Leaders from the international community will
convene to present their work, experiences, observations, and
opinions on the benefits and unmet challenges of cell-based
therapies.

• At 4:30 PM on Wednesday, January 25, Andrew L. Pecora, MD,
  FACP, Chief Medical Officer of NeoStem, will speak on an
  industry session entitled "Focus on Acute Injury Technologies."
• At 9:20 AM on Thursday, January 26, Arshed A. Quyyumi, MD,
  FRCP, FACC, principal investigator of the PreSERVE AMI Phase
  2 trial^[4] and
  Professor of Medicine and Cardiology at Emory University,
  will speak on a panel entitled "Early and Next Phase Studies"
  within a session entitled "Acute Injury: STEMI and NSTEMI".
• From 7:30 to 8:30 AM on Friday, January 27, Robert A.
  Preti, PhD, President of Progenitor Cell
  Therapy^[5] will
  speak as part of Industry Session III entitled "Focus on
  Procedure, Systems Management, and Advanced Technologies."

Dr. Pecora said, "As a presenter at the first industry
session, I look forward to informing industry leaders about the
PreSERVE Phase 2 clinical trial for AMI which is now open for
enrollment and may provide data readout 18 months from the
first patient enrollment, as well as discussing the recent
patent issued to use the Amorcyte technology beyond
cardiovascular disease." 

Dr. Robin L. Smith, Chairman and CEO of NeoStem, said, "This
conference represents validation that the development of
cell therapies for diseases outside of bone marrow
transplantation is progressing as represented by their current
clinical data. Our acquisition of Amorcyte last year has
positioned NeoStem to be a leader in the cell therapy
cardiovascular space. We are excited to be a part of the
developing science represented by this important conference and
share our expertise represented by the progress with Amorcyte
and our capabilities to assist the field with the manufacturing
services of PCT."

About the Cardiovascular Research Foundation

According to the Cardiovascular Research Foundation, their role
in interventional cardiovascular medicine is unique: conducting
research on therapies, pharmacology, and devices during the
earliest stages of development, confirming safety and efficacy
in human clinical trials, and educating the medical community
regarding appropriate use of these new procedures and
technologies. By providing research, evaluation, and education
under one roof, CRF has a unique ability to generate important
research questions, test and refine groundbreaking new
therapies, and ensure that these treatments are available to
patients at the earliest opportunity. For more information,
please visit http://www.celltherapy.crf.org^[6].

About NeoStem, Inc. and Amorcyte, LLC, a NeoStem company

NeoStem, Inc. ("NeoStem") is a leader in the development and
manufacture of cell therapies. NeoStem has a strategic
combination of revenues, including that which is derived from
the contract manufacturing services performed by Progenitor
Cell Therapy, LLC, a NeoStem company. That manufacturing base
is one of the few cGMP facilities available for contracting in
the burgeoning cell therapy industry, and it is the combination
of PCT's core expertise in manufacturing and NeoStem's
extensive research capabilities that positions the company as a
leader in cell therapy development. Amorcyte, LLC, also a
NeoStem company, is developing a cell therapy for the treatment
of cardiovascular disease. Amorcyte's lead compound, AMR-001,
represents NeoStem's most clinically advanced therapeutic and
is open for enrollment in a Phase 2 trial for the preservation
of heart function after a heart attack.  Amorcyte expects
to begin a Phase 1 clinical trial in 2012 for AMR-001 for the
treatment of patients with congestive heart failure. Athelos
Corporation, also a NeoStem company, is developing a T-cell
therapy for a range of autoimmune conditions with our partner
Becton-Dickinson.  NeoStem's pre-clinical assets include
its VSEL™ Technology platform for regenerative medicine, which
NeoStem believes to be an endogenous, pluripotent,
non-embryonic stem cell that has the potential to change the
paradigm of cell therapy as we know it today.

For more information on NeoStem and Amorcyte, please visit
http://www.neostem.com^[7] and
http://www.amorcyte.com^[8].

Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward looking statements
include statements herein with respect to the successful
execution of the Company's business and medical strategy,
including with respect to the successful development of AMR-001
and other cell therapies, about which no assurance can be
given. The Company's actual results could differ materially
from those anticipated in these forward- looking statements as
a result of various factors. Factors that could cause future
results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk
Factors" described in the Company's definitive proxy statement
filed with the Securities and Exchange Commission on September
16, 2011 and in the Company's periodic filings with the
Securities and Exchange Commission. The Company's further
development is highly dependent on future medical and research
developments and market acceptance, which is outside its
control.

References

1. ^{^} NeoStem, Inc.
   (us.lrd.yahoo.com)
2. ^{^} PreSERVE Phase 2 clinical
   trial (us.lrd.yahoo.com)
3. ^{^} Progenitor Cell Therapy, LLC
   (us.lrd.yahoo.com)
4. ^{^} PreSERVE AMI Phase 2 trial
   (us.lrd.yahoo.com)
5. ^{^} Progenitor Cell Therapy
   (us.lrd.yahoo.com)
6. ^{^} http://www.celltherapy.crf.org
   (us.lrd.yahoo.com)
7. ^{^} http://www.neostem.com
   (us.lrd.yahoo.com)
8. ^{^} http://www.amorcyte.com
   (us.lrd.yahoo.com)
9. ^{^} gogawa@troutgroup.com
   (finance.yahoo.com)
10. ^{^} rsmith@neostem.com
    (finance.yahoo.com)